Loading
Every dated change on the records linked to Mantle cell lymphoma, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
Median progression-free survival 66.
Progression-free survival adjusted hazard ratio 0.
Median progression-free survival 31.
Three-year failure-free survival 88 percent with ibrutinib added to induction, transplant and maintenance against 72 percent with standard induction and transplant (hazard ratio 0.
Ibrutinib replaces transplant in fit patients; acalabrutinib + BR improves PFS first line in older patients.
Relapsed/refractory mantle cell lymphoma
Relapsed or refractory CLL/SLL; relapsed or refractory mantle cell lymphoma
High objective and complete response rates with durable remissions in mantle cell lymphoma after BTK inhibitor failure; approved in July 2020.
First CAR-T for MCL: 93% response after BTKi failure.